Notice Announcing the Systems Biology Data Platform Leveraging the Accelerating Medicines Partnership (OT2)
Notice Number:
NOT-RM-24-008

Key Dates

Release Date:

March 18, 2024

Related Announcements

None

Issued by

Office of Strategic Coordination (Common Fund)

Purpose

This Notice announces the publication of a new Research Opportunity Announcement (ROA), Systems Biology Data Platform Leveraging the Accelerating Medicines Partnership (OTA-24-008) and the key dates for submitting Letters of Intent (LOI) and full proposals. The ROA was released on the NIH Common Fund website.

Letter of Intent (LOI) Due Date (Optional): April 3, 2024 by 5:00 PM local time of applicant. Submitting an LOI is strongly encouraged but is not required for subsequent submission of a full application.

Application Due Date: May 15, 2024 by 5:00 PM local time of applicant organization. Late applications to this ROA will not be accepted.

This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have an exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems or to seize new opportunities that offer the potential for rapid progress.

This initiative is part of the Venture Program, a new effort within the Common Fund to support novel, short-term, bold initiatives that have the potential for significant impact in biomedical and behavioral research. Venture initiatives are innovative and nimble, introducing additional flexibility for the Common Fund to tackle a wider variety of research topics. Venture initiatives embrace scientific risk and have strong potential to accelerate science rapidly. These short-term initiatives will be supported for a maximum of 3 years and will include clearly defined goals and milestones to facilitate rigorous measurement of research progress. Each Venture initiative is expected to produce specific deliverables, which can be new knowledge, methods, technologies, or devices.

The purpose of this announcement is to invite applications from eligible organizations to establish the Systems Biology Data Platform (SysBio) Leveraging the Accelerating Medicines Partnership (AMP). Award(s) made through this announcement will support SysBio by providing technical and administrative coordination and support to enable broad use of the data sets and knowledge generated by the different initiatives funded by AMP and, potentially, other complementary data sets. The recipient(s) will work collaboratively with the AMP data platforms and the NIH Institutes, Centers and Offices that support them, to coordinate the activities needed to integrate data from across the AMP ecosystem. The end product of SysBio will constitute a platform to enable the research community to query data across the different tissues and conditions studied in the different AMP projects from a single access point.

An Informational Webinar will be held for potential applicants on March 18th at 3 pm EDT. Registration information for the Webinar and additional information on the ROA will be posted on the SysBio Frequently Asked Questions webpage. Materials from the Webinar will be made available on that website for those unable to attend.

Award Information

The Common Fund may allocate up to $4,800,000 per year total costs (direct + F&A) for up to three years to develop and establish SysBio. The award(s) are contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Should multiple awards be made under this solicitation, how funds may be split between awards has not been predetermined and will depend on (1) the objectives proposed by the applicants and how well they fit within the goals of SysBio, (2) the quality of the applications received, (3) availability of funds, and (4) programmatic priorities, but the total for all costs for all awards will be no more than $4,800,000 per year for up to three years.

Eligibility Information

Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

The following entities are eligible to apply under this ROA:

Higher Education Institutions

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions
  • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)  

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Faith-based or Community-based Organizations
  • Regional Organizations

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • American Indian/Native American Tribal Governments (Federally Recognized)
  • American Indian/Native American Tribal Governments (Other than Federally Recognized)
  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession

Other

  • Independent School Districts

Native American Tribal Organizations (other than federally recognized tribal governments) 

Inquiries

Please direct all inquiries to:

Anthony Kirilusha, Ph.D. 
Program Leader 
Office of Strategic Coordination (OSC) 
Division of Program Coordination, Planning, and Strategic Initiatives  
Office of the Director (OD), NIH
Email: [email protected] and [email protected]